PlasmaTech Biopharmaceuticals, Inc. Announces Pricing of $14,000,000 Public Offering and Listing on NASDAQ

Print E-mail
Saturday, 20 December 2014 00:26

DALLAS and NEW YORK--PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care in critical areas, announced the pricing of an underwritten public offering of 3,500,000 shares of common stock, and warrants to purchase up to an aggregate 3,500,000 shares of common stock, at an offering price of $4.00 per share and $.01 per warrant.  

Read more...
 

The Bakken Invitation Announces 2014 Honorees: 10 Inspiring People Who Live On and Give On

Print E-mail
Monday, 08 December 2014 11:18
MINNEAPOLIS--Medtronic (NYSE: MDT) today announced the names of 10 people from around the world who will be honored as part of the Bakken Invitation, a global program launched in 2013 that celebrates and connects people who, with the help of medical technology, have overcome health challenges and are now making a difference in their communities.
Read more...
 

Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes

Print E-mail
Thursday, 04 December 2014 22:17

HAIFA, ISRAEL--Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PSTI), a leading developer of placenta-based cell therapy products, announced today that it has entered into a long-term collaboration agreement with Hadassah Medical Center in Jerusalem.

Read more...
 

CEL-SCI Quarterly Patient Enrollment in Its Head and Neck Cancer Phase III Trial Increases Eight Fold Over Same Prior Year Period

Print E-mail
Tuesday, 02 December 2014 18:51
Vienna, VA--CEL-SCI Corporation (NYSE MKT: CVM) today announced  that during the past three months it has enrolled 58 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). 
Read more...
 

Actinium Receives Orphan-Drug Designation from FDA for Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients

Print E-mail
Monday, 01 December 2014 18:45

NEW YORK, NY--Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the US Food and Drug Administration (FDA) has granted orphan-drug designation for Actimab-A, an alpha radiolabeled antibody being developed for newly diagnosed AML in patients over the age of 60. Actimab-A is currently in a multicenter Phase 1/2 trial clinical trial.

Read more...
 

Follow up on Purdue's approval of Hysingla - Relmada Therapeutics

Print E-mail
Thursday, 20 November 2014 20:19

New York-based Relmada Therapeutics (RLMD) has reinvented four proven and promising drug candidates with novel delivery systems to create new drugs for new indications.

Read more...
 

RELMADA THERAPEUTICS APPOINTS MICHAEL BECKER AS SENIOR VICE PRESIDENT OF FINANCE AND CORPORATE DEVELOPMENT

Print E-mail
Tuesday, 04 November 2014 19:51

New York, NY--Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Michael D. Becker as senior vice president of finance and corporate development, effective immediately.

Read more...
 

LA BioMed Receives Phase II Grand Challenges Explorations Funding

Print E-mail
Monday, 03 November 2014 20:41

LOS ANGELES - Los Angeles Biomedical Research Institute ( LA BioMed) announced today that it will receive Phase II funding through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables individuals worldwide to test bold ideas to address persistent health and development challenges.

Read more...
 

Case Western Reserve University to Study Pluristem's PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases

Print E-mail
Monday, 27 October 2014 15:59

HAIFA, Israel--Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-derived cell therapy products, announced today that researchers at Case Western Reserve University will conduct a preclinical study of the Company's PLacental eXpanded (PLX)-RAD cells.

Read more...
 

Actinium Announces Collaboration with Albert Einstein College of Medicine on New Actinium Program

Print E-mail
Monday, 27 October 2014 15:23

 

New York, NY--Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, and Albert Einstein College of Medicine of Yeshiva University, a research-intensive medical school in Bronx, NY, started development of an antibody construct labeled with actinium 225 using a novel technology that potentially allows for the expansion of use of the Company’s proprietary platform and enables further manufacturing improvements of alpha therapy technology based drug candidates.
Read more...
 
<< Start < Prev 1 3 > End >>

Page 1 of 3

Newsletter

BioMedReports Bone loss drugs may help prevent endometrial cancer http://t.co/Se1b6YF9UM
6hreplyretweetfavorite
BioMedReports U.S. FDA approves AbbVie all-oral hepatitis C treatment... http://t.co/oZCrnjc9km
BioMedReports FDA grants accelerated approval to AstraZeneca's ovary cancer drug... http://t.co/XxwyJeQVzN
Benzinga.com supporter Seeking Alpha Certified